ENLVNasdaqFinance ServicesUS GAAP · USD

Enlivex Ltd.

Enlivex Ltd. is an Israel-based clinical-stage biotechnology company focused on developing Allocetra™, an immunotherapy platform for inflammatory conditions associated with aging, including age-related osteoarthritis. The company is headquartered in Nes Ziona, Israel and is publicly listed on Nasdaq; it also manages a digital asset treasury tied to the Rain prediction markets protocol.

Kysy yhtiöstä

Liiketoiminta

Osuus liikevaihdosta
Clinical-stage immunotherapy60 %

Development of Allocetra™ and related therapeutic candidates for inflammatory and aging-related conditions.

Digital asset treasury40 %

Treasury holdings and related market exposure built around the RAIN token and prediction markets ecosystem.

Asiakkaat

Enlivex's therapeutic work is aimed at patients with inflammatory conditions associated with aging, especially age-related osteoarthritis, through future clinical and commercial pathways. Its treasury strategy does not involve conventional product customers in the usual sense; rather, it is exposed to token holders, exchange participants, and the broader digital-asset market that determines the value of RAIN.

Patients with age-related inflammatory disease

Future end users of Allocetra™ if the therapy advances and is commercialized for osteoarthritis or related indications.

Clinical investigators and trial sites

Hospitals, physicians, and research centers that conduct the studies needed to advance Allocetra™.

Pharma partners and licensees

Potential collaborators that may buy rights, co-develop assets, or fund development programs.

Digital-asset market participants

Users and traders whose demand, liquidity, and pricing determine the value of RAIN treasury holdings.

Tokenized-equity investors

Non-U.S. investors gaining exposure to Enlivex ordinary shares through ENLVon on Ondo Global Markets.

Strategia

Enlivex is pursuing a dual strategy: advance Allocetra™ as a clinical-stage immunotherapy while maintaining a treasury positioned around the Rain prediction markets protocol. This creates optionality between long-duration biotech development and exposure to a digital-asset ecosystem that can support treasury value and market visibility.

Advance Allocetra™ clinical programsKeskipitkä aikaväli

Clinical progress is the core value driver for the biotechnology business.

Scale and preserve treasury exposureLyhyt aikaväli

RAIN holdings are intended to support net asset value and strategic flexibility.

Expand investor access through tokenizationLyhyt aikaväli

Tokenized distribution can broaden the shareholder base and improve liquidity access.

Maantiede

Enlivex is headquartered in Nes Ziona, Israel, and its operating footprint is centered on Israeli corporate and research activities. The company is listed in the United States on Nasdaq, while its treasury exposure reaches into global digital-asset markets through RAIN and tokenized equity distribution channels.

Riskit

Enlivex faces typical clinical-development risk because Allocetra™ must prove safety, efficacy, and commercial relevance before it can create operating value. The treasury strategy adds a separate layer of risk from highly volatile digital-asset prices, liquidity, exchange access, and evolving regulatory treatment of crypto assets.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Digital asset volatility1Clinical development failure2Regulatory uncertainty in crypto3Financing and dilution risk4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Digital asset volatilityVaikutus: KorkeaTodennäköisyys: Korkea

    The company’s treasury value depends heavily on RAIN token price, liquidity, and trading volume.

    Kohdistuu: RAIN holdings

  2. Clinical development failureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Allocetra™ is still in clinical-stage development and may not demonstrate sufficient safety or efficacy.

    Kohdistuu: Allocetra™ program

  3. Regulatory uncertainty in cryptoVaikutus: KeskitasoTodennäköisyys: Korkea

    Digital assets face changing legal, commercial, and tax frameworks across jurisdictions.

    Kohdistuu: Treasury strategy

  4. Financing and dilution riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Biotech development and treasury execution may require additional capital or convertible financing.

    Kohdistuu: Corporate funding

Kysy Clarifolta: Enlivex Ltd.

Kirjanpito

Harkinnanvaraiset erät
Fair value of RAIN tokens

Treasury holdings are valued using market data, so price changes directly affect reported asset values and results.

Vaikutus: Can create large unrealized gains or losses

Convertible promissory note

The senior secured convertible note may require separation of debt and equity-like features or derivative accounting.

Vaikutus: Affects interest expense, liability balance, and dilution analysis

R&D expense recognition

Clinical trial and development costs are typically expensed as incurred, shaping operating results.

Vaikutus: Determines timing of biotech spending recognition

Digital asset disclosures

Treasury strategy depends on clear disclosure of holdings, valuation date, and market reference prices.

Vaikutus: Important for NAV and liquidity analysis

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Enliven Therapeutics, Inc.

ELVN · Pharmaceutical Preparations

ENvue Medical, Inc.

FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies

NeuroSense Therapeutics Ltd.

NRSN · Pharmaceutical Preparations

InflaRx N.V.

IFRX · Pharmaceutical Preparations

Intellia Therapeutics, Inc.

NTLA · In Vitro & In Vivo Diagnostic Substances

ZyVersa Therapeutics, Inc.

ZVSA · Pharmaceutical Preparations

Päivitetty: 28.9.2026